Ingegerd Odar‐Cederlöf

2.2k total citations
53 papers, 1.7k citations indexed

About

Ingegerd Odar‐Cederlöf is a scholar working on Nephrology, Pediatrics, Perinatology and Child Health and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Ingegerd Odar‐Cederlöf has authored 53 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Nephrology, 15 papers in Pediatrics, Perinatology and Child Health and 12 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Ingegerd Odar‐Cederlöf's work include Dialysis and Renal Disease Management (12 papers), Pharmacological Effects and Toxicity Studies (12 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Ingegerd Odar‐Cederlöf is often cited by papers focused on Dialysis and Renal Disease Management (12 papers), Pharmacological Effects and Toxicity Studies (12 papers) and Pharmacogenetics and Drug Metabolism (6 papers). Ingegerd Odar‐Cederlöf collaborates with scholars based in Sweden, United States and United Kingdom. Ingegerd Odar‐Cederlöf's co-authors include Magnus Borga, Folke Sjöqvist, Christer von Bahr, Ingvar Sjöholm, Anita Kober, Marcus M. Reidenberg, C. Johansson, Kenneth M. Piafsky, Anders Helldén and Juliette Säwe and has published in prestigious journals such as New England Journal of Medicine, The Lancet and SHILAP Revista de lepidopterología.

In The Last Decade

Ingegerd Odar‐Cederlöf

53 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Ingegerd Odar‐Cederlöf Sweden 23 390 293 274 260 256 53 1.7k
B Beermann Sweden 27 380 1.0× 358 1.2× 403 1.5× 167 0.6× 388 1.5× 98 2.4k
U. C. Dubach Switzerland 25 241 0.6× 243 0.8× 742 2.7× 241 0.9× 245 1.0× 101 2.2k
Richard A. Robson New Zealand 29 270 0.7× 388 1.3× 480 1.8× 348 1.3× 330 1.3× 87 2.8k
Stefan Russmann Switzerland 26 208 0.5× 499 1.7× 263 1.0× 240 0.9× 195 0.8× 64 2.2k
David M. Kornhauser United States 24 160 0.4× 247 0.8× 671 2.4× 113 0.4× 312 1.2× 48 2.3k
Larry A. Bauer United States 25 968 2.5× 259 0.9× 141 0.5× 152 0.6× 656 2.6× 74 2.4k
Walter Ziegler Switzerland 25 197 0.5× 276 0.9× 404 1.5× 163 0.6× 419 1.6× 82 2.5k
Matthew Doogue New Zealand 25 360 0.9× 195 0.7× 757 2.8× 199 0.8× 253 1.0× 94 3.1k
Gillian M. Shenfield Australia 28 322 0.8× 380 1.3× 200 0.7× 75 0.3× 349 1.4× 114 2.3k
Ralph E. Cutler United States 32 568 1.5× 210 0.7× 485 1.8× 767 3.0× 459 1.8× 80 3.0k

Countries citing papers authored by Ingegerd Odar‐Cederlöf

Since Specialization
Citations

This map shows the geographic impact of Ingegerd Odar‐Cederlöf's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingegerd Odar‐Cederlöf with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingegerd Odar‐Cederlöf more than expected).

Fields of papers citing papers by Ingegerd Odar‐Cederlöf

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingegerd Odar‐Cederlöf. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingegerd Odar‐Cederlöf. The network helps show where Ingegerd Odar‐Cederlöf may publish in the future.

Co-authorship network of co-authors of Ingegerd Odar‐Cederlöf

This figure shows the co-authorship network connecting the top 25 collaborators of Ingegerd Odar‐Cederlöf. A scholar is included among the top collaborators of Ingegerd Odar‐Cederlöf based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingegerd Odar‐Cederlöf. Ingegerd Odar‐Cederlöf is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Helldén, Anders, et al.. (2015). Development of a computerised decisions support system for renal risk drugs targeting primary healthcare. BMJ Open. 5(7). e006775–e006775. 9 indexed citations
2.
Wyss, Katja, et al.. (2015). Which Medication Is the Patient Taking at Admission to the Emergency Ward? Still Unclear Despite the Swedish Prescribed Drug Register. PLoS ONE. 10(6). e0128716–e0128716. 2 indexed citations
3.
Helldén, Anders, Ingegerd Odar‐Cederlöf, Göran Nilsson, et al.. (2013). Renal function estimations and dose recommendations for dabigatran, gabapentin and valaciclovir: a data simulation study focused on the elderly. BMJ Open. 3(4). e002686–e002686. 32 indexed citations
4.
Al‐Tawil, Nabil, et al.. (2012). Pharmacokinetics of transdermal buprenorphine patch in the elderly. European Journal of Clinical Pharmacology. 69(2). 143–149. 44 indexed citations
5.
Helldén, Anders, Ulf Bergman, Karin Hellgren, et al.. (2010). Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9. European Journal of Clinical Pharmacology. 66(8). 791–795. 9 indexed citations
6.
Helldén, Anders, et al.. (2007). Death delusion. BMJ. 335(7633). 1305–1305. 11 indexed citations
7.
Odar‐Cederlöf, Ingegerd, et al.. (2007). Intradialytic parenteral nutrition abolishes the increase of insulin-like growth factor binding protein-1 (IGFBP-1) during hemodialysis and elevates the IGF-I/IGFBP-1 ratio, an anticatabolic effect?. e-SPEN the European e-Journal of Clinical Nutrition and Metabolism. 2(5). e97–e102. 2 indexed citations
8.
Helldén, Anders, Jan Lycke, Tatiana Vander, et al.. (2006). The aciclovir metabolite CMMG is detectable in the CSF of subjects with neuropsychiatric symptoms during aciclovir and valaciclovir treatment. Journal of Antimicrobial Chemotherapy. 57(5). 945–949. 55 indexed citations
9.
Helldén, Anders, Ingegerd Odar‐Cederlöf, Lisbeth Barkholt, et al.. (2003). High serum concentrations of the acyclovir main metabolite 9-carboxymethoxymethylguanine in renal failure patients with acyclovir-related neuropsychiatric side effects: an observational study. Nephrology Dialysis Transplantation. 18(6). 1135–1141. 76 indexed citations
10.
Bergman, Anders, Ingegerd Odar‐Cederlöf, Lars Westman, et al.. (2002). Diltiazem infusion for renal protection in cardiac surgical patients with preexisting renal dysfunction. Journal of Cardiothoracic and Vascular Anesthesia. 16(3). 294–299. 28 indexed citations
11.
Odar‐Cederlöf, Ingegerd, et al.. (1998). Is neuropeptide Y a contributor to volume-induced hypertension?. American Journal of Kidney Diseases. 31(5). 803–808. 25 indexed citations
12.
Odar‐Cederlöf, Ingegerd, et al.. (1996). Decreased bioavailability of insulin-like growth factor-I, a cause of catabolism in hemodialysis patients?. PubMed. 6(3). 137–43. 25 indexed citations
13.
Bergman, Anders, Ingegerd Odar‐Cederlöf, & Lars Westman. (1995). Renal and Hemodynamic Effects of Diltiazem After Elective Major Vascular Surgery—A Potential Renoprotective Agent?. Renal Failure. 17(2). 155–163. 7 indexed citations
14.
Bergman, Anders, K Fält, Ingegerd Odar‐Cederlöf, Lars Westman, & R Takolander. (1994). Calcitonin Gene-Related Peptide Attenuates Experimental Ischemic Renal Failure in a Rat Model of Reversible Renal Ischemic Insult. Renal Failure. 16(3). 351–357. 5 indexed citations
15.
Bergman, Åke, Ingegerd Odar‐Cederlöf, Elvar Theodorsson, & L. Westman. (1994). Renal effects of human atrial natriuretic peptide in patients after major vascular surgery. Acta Anaesthesiologica Scandinavica. 38(7). 667–671. 1 indexed citations
16.
Yue, Qun‐Ying, Christer von Bahr, Ingegerd Odar‐Cederlöf, & Juliette Säwe. (1990). Glucuronidation of Codeine and Morphine in Human Liver and Kidney Microsomes: Effect of Inhibitors. Pharmacology & Toxicology. 66(3). 221–226. 56 indexed citations
17.
Yue, Qun‐Ying, Ingegerd Odar‐Cederlöf, Jan‐Olof Svensson, & Juliette Säwe. (1988). Glucuronidation of Morphine in Human Kidney Microsomes. Pharmacology & Toxicology. 63(5). 337–341. 45 indexed citations
18.
Alván, Gunnar, H Asaba, Jonas Bergström, et al.. (1982). [Acute theophylline poisoning treated with combined hemoperfusion and hemodialysis].. PubMed. 79(9). 745–6. 3 indexed citations
19.
Piafsky, Kenneth M., Magnus Borga, Ingegerd Odar‐Cederlöf, C. Johansson, & Folke Sjöqvist. (1978). Increased Plasma Protein Binding of Propranolol and Chlorpromazine Mediated by Disease-Induced Elevations of Plasma α1Acid Glycoprotein. New England Journal of Medicine. 299(26). 1435–1439. 237 indexed citations
20.
Odar‐Cederlöf, Ingegerd, P. K. M. Lunde, & Folke Sjöqvist. (1970). ABNORMAL PHARMACOKINETICS OF PHENYTOIN IN A PATIENT WITH URÆMIA. The Lancet. 296(7677). 831–832. 65 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by B Beermann Breakdown of academic impact, for papers by U. C. Dubach Breakdown of academic impact, for papers by Richard A. Robson Breakdown of academic impact, for papers by Stefan Russmann Breakdown of academic impact, for papers by David M. Kornhauser Breakdown of academic impact, for papers by Larry A. Bauer Breakdown of academic impact, for papers by Walter Ziegler Breakdown of academic impact, for papers by Matthew Doogue Breakdown of academic impact, for papers by Gillian M. Shenfield Breakdown of academic impact, for papers by Ralph E. Cutler
Rankless by CCL
2026